Kiniksa Pharmaceuticals saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, with an increase from 79 to 87.
Looking For The Best Stocks To Buy And Watch? Start Here
IBD's unique rating tracks price action with a 1 (worst) to 99 (best) score. The score shows how a stock's price movement over the trailing 52 weeks compares to all the other stocks in our database.
Decades of market research shows that the top-performing stocks often have an 80 or better RS Rating in the early stages of their moves.
Kiniksa Pharmaceuticals broke out earlier, but has fallen back below the prior 30.69 entry from a flat base. If a stock you're tracking breaks past a buy point then declines 7% or more below the original entry price, it's considered a failed base. It's best to wait for the stock to form a new consolidation and breakout. Also understand that the most recent consolidation is a later-stage base, and such bases are more prone to failure.
Kiniksa Pharmaceuticals reported 0% EPS growth in its most recent report. Sales rose 44%.
Kiniksa Pharmaceuticals earns the No. 3 rank among its peers in the Medical-Biomed/Biotech industry group. Incyte is the No. 1-ranked stock within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
